Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100U7ET
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Total assets¥95.9bnat 2024-06-30Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥57.7bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥37.1bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 586
ItemContextValueUnit
Profit loss before tax IFRSPrior1YTDDuration-1110932000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember28480960000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7652665000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember36133625000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration36133625000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember177534000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember177534000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-177534000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember28480960000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7830199000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember36311160000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-177534000JPY
Revenue IFRSCurrentYTDDuration36133625000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember24740819000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember-46535000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember24694283000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSCurrentYTDDuration24694283000JPY
Business combination related expenses IFRSCurrentYTDDuration45000000JPY
Operating profit loss IFRSCurrentYTDDuration24649283000JPY
Finance income IFRSCurrentYTDDuration335214000JPY
Finance costs IFRSCurrentYTDDuration136342000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-105927000JPY
Profit loss before tax IFRSCurrentYTDDuration24742228000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-08-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第19期中(自 2024年１月１日 至 2024年６月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)ペプチドリーム株式会社
Company name in english cover pageFilingDateInstantPeptiDream Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO 　　　　リード・パトリック
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号
Telephone number address of registered headquarter cover pageFilingDateInstant044(270)1300
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)ＩＲ広報部ディレクター　　沖本　優子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号
Telephone number nearest place of contact cover pageFilingDateInstant044(223)6612
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)ＩＲ広報部ディレクター　　沖本　優子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE27486
Fund codeFilingDateInstant－
Security codeFilingDateInstant45870
Filer name in japaneseFilingDateInstant
Original text (Japanese)ペプチドリーム株式会社
Filer name in englishFilingDateInstantPeptiDream Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass